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In recent years, the use of in-feed antibiotics for growth and disease prevention in livestock production has been
under severe scrutiny. The use and misuse of in-feed antibiotics has led to problems with drug residues in animal
products and increased bacterial resistance. Chicken egg yolk antibodies (IgY) have attracted considerable attention
as an alternative to antibiotics to maintain swine health and performance. Oral administration of IgY possesses
many advantages over mammalian IgG such as cost-effectiveness, convenience and high yield. This review presents
an overview of the potential to use IgY immunotherapy for the prevention and treatment of swine diarrhea
diseases and speculates on the future of IgY technology. Included are a review of the potential applications of IgY
in the control of enteric infections of either bacterial or viral origin such as enterotoxigenic Escherichia coli,
Salmonella spp., rotavirus, porcine transmissible gastroenteritis virus, and porcine epidemic diarrhea virus. Some
potential obstacles to the adoption of IgY technology are also discussed.
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Antibiotics have been widely used in the swine industry
for more than 50 years. The efficacy of antibiotics in
increasing growth rate, improving feed utilization, and
reducing incidence of disease is well documented [1].
In general, sub-therapeutic levels of antibiotics in swine
diets increase the growth rate by an average of 16 % in
weanling pigs, 11 % in growing pigs, and 4 % in
growing-finishing pigs [1]. In addition, antibiotics are
also used for disease prevention (prophylactic doses)
and treatment (therapeutic doses). However, serious
concerns have arisen with regard to the potential risks
for human health including drug residues in meat prod-
ucts and increased bacterial resistance due to the use
and misuse of in-feed antibiotics [2]. As a result, the
European Union has totally banned the use of antibi-
otics for growth promotion since January 2006 [3],
while the US Food and Administration (FDA) has been* Correspondence: xiaoyuli@dlut.edu.cn
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Diarrheal disease is a frequent cause of heavy eco-
nomic losses for swine producers. A major challenge
currently facing the swine industry is to develop alter-
native means for controlling diarrhea in young pigs
(particularly neonatal and early-weaned piglets) that are
not only cost effective, but also allow for sustainable
pork production. In the past two decades, a variety of
materials have been tested as effective alternatives to
antibiotics to maintain swine health and performance.
The most widely researched alternatives include en-
zymes [5], organic acids [6], pro- and prebiotics [7–9],
herbal extracts [10, 11] and neutraceuticals such as
copper and zinc [12, 13]. However, these alternatives
produce limited growth promotion and protection
against pathogens.
Recently, egg yolk antibodies, generally referred to as
IgY, have attracted considerable interest as an alternative
to antibiotics for growth promotion in the presence of
disease causing organisms [14]. IgY possesses a large
number of advantages over mammalian IgG such as
cost-effectiveness, convenience, and high yield [15]. Oralistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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to be highly effective against a variety of intestinal
pathogens which cause diarrhea in animals and hu-
man such as enterotoxigenic Escherichia coli (ETEC),
Salmonella spp., bovine and human rotaviruses, bo-
vine coronavirus, porcine transmissible gastroenteritis
virus (TGEV), and porcine epidemic diarrhea virus
(PEDV) [14, 16].
Following a brief description of IgY technology and
the advantages of IgY, this review will focus on the
potential to use specific IgY as a production enhancer in
swine production, and discuss the potential obstacles to
the adoption of IgY technology.IgY technology
As described more than 100 years ago, Klemperer [17]
first demonstrated that avian maternal antibodies are
transferred from serum to egg yolk in order to protect
the developing embryo from potential pathogens but at
that time there was no scientific application for this
knowledge. However, when animal welfare became a
matter of serious ethical concern for the scientific com-
munity, the results of Klemperer began to receive more
interest, particularly since the 1980s.
Since 1996, IgY technology (i.e. the production and
use of IgY) has become an internationally accepted prac-
tice [18]. In 1996, the European Centre for the Valid-
ation of Alternative Methods (ECVAM) workshop
strongly recommended that IgY should be used as an al-
ternative to mammalian antibodies [19]. In 1999, IgY
technology was approved as an alternative method for
supporting animal welfare by the Veterinary Office of
the Swiss Government (Office Vétérinaire Fédéral).
Details concerning the production of specific IgY have
been reviewed by Schade et al. (2005) [20]. Briefly, in
order to produce specific IgY antibodies, laying hens are
immunized with specific foreign pathogens which induce
immune responses, including the production of anti-
bodies with activity against these specific disease condi-
tions. These antibodies are then transferred to the egg
yolk and deposited in large quantities. Booster immuni-
zations are usually given to ensure continued transfer of
antibodies from the hen’s serum to the egg yolk. These
antibodies are then extracted from the egg yolk and
processed to be administered directly to the animal or
incorporated into diets.
Antibodies can be administered in several forms includ-
ing whole egg powder, whole yolk powder, a water-soluble
fraction powder or purified IgY. Antibody production and
titer development as a result of immunization are not very
predictable. Variables influencing immunization include
the antigen (dose, MW), type of adjuvant used, route of
immunization, immunization frequency and the chickenitself (such as housing conditions, age, breed, egg
laying capacity).
Advantages of IgY
The use of chickens as the immunization host for anti-
body production provide a number of advantages over
production methods using mammals. The most signifi-
cant advantage is that egg collection is non-invasive
compared with the stressful bleeding of animals to ob-
tain serum. In addition, the high and long-lasting titer
produced in chickens reduces the need for frequent
booster injections. Another advantage is that the pro-
duction of IgY antibodies against highly conserved mam-
malian proteins is more successful in chickens than in
other mammals [21] and requires much less antigen to
induce an efficient immune response due to the phylo-
genetic distance between chickens and mammals [22].
A hen can be considered as a small "factory" for anti-
body production. One hen can produce more than
22.5 g of total IgY per year of which 2 to 10 % are spe-
cific antibodies [14]. This extraordinary quantity is
equivalent to the production of 4.3 rabbits over the
course of a year. The cost for maintaining laying hens
are also lower than those for mammals such as rabbits
[20]. Therefore, egg yolk offers a more hygienic, cost-
efficient, convenient and rich source of antibodies com-
pared with traditional production methods using mam-
mals. In contrast to antibiotics, the use of IgY is
environmentally-friendly and elicits no undesirable side
effects, disease resistance or toxic residues [23].
In terms of function, unlike mammalian IgG, IgY does
not activate mammalian complement and also does not
interact with mammalian Fc and complement receptors.
As well, IgY does not bind to protein A, protein G or
rheumatoid factor [15]. These differences provide great
advantages for the successful application of IgY technol-
ogy in many research areas, diagnostics [24], antibiotic-
alternative therapy [15] and xenotransplantation [25].
Mode of action
The exact mechanisms through which IgY counteracts
pathogen activity have not been determined. However,
several mechanisms have been proposed by Xu et al.
(2011) [14] including agglutination of bacteria, inhibition
of adhesion, as well as opsonization followed by phago-
cytosis and toxin neutralization. Among these, inhibition
of adhesion is considered the primary mechanism by
which specific IgY functions. Briefly, IgY antibodies gen-
erated against intestinal disease causing organisms may
reduce the incidence of disease by preventing the attach-
ment of pathogens to the intestine, such as blocking the
mucosal receptor, interfering with binding to mucins, or
neutralizing the colonization factor (such as the outer
membrane protein, lipopolysaccharide, fimbriae (or pili),
Fig. 1 Possible primary mode of action by which IgY protects pigs against E coli K88 induced diarrhea. Modified from Hatta et al. [85]
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by which IgY protects pigs against E coli K88 induced
diarrhea is illustrated in Fig. 1.
IgY applications in swine production
Diarrhoea in neonatal and post-weaning pigs can be
caused by a number of causative agents and has be-
come a serious problem in the swine industry due to
the trend towards large intensive herds and early wean-
ing (i.e. 14–21 rather than 21–28 days of age). The
potential applications for using orally administered IgY
in the control of enteric infections of either bacterial or
viral origin in piglets have been studied at length and
are summarized in Tables 1 and 2.
Antimicrobial and performance effects
Enterotoxigenic Escherichia coli
Diarrhea due to enterotoxigenic Escherichia coli (ETEC) is
by far the most common enteric colibacillosis encountered
in neonatal and post-weaned pigs [27–29]. ETEC can
cause diarrhea in piglets by colonization in the small
intestine and thereafter through the production of
either one or two enterotoxins namely heat-labile
enterotoxin (LT) and heat-stable enterotoxins (ST),
which induce massive fluid and electrolyte secretion
into the gut lumen [30].
The strains of E. coli associated with intestinal
colonization which cause severe diarrhea are those ex-
pressing the K88 (or F4), K99 (or F5), 987P (or F6), F18
and F41 fimbrial adhesions. These fimbrial adhesions
mediate the adhesion of E. coli to the epithelial mucosa
lining of the intestine and thereby contribute to their
virulence. Among the different ETEC, those expressing
the K88+ fimbrial antigen are the most prevalent forms
causing E. coli infection world-wide [31]. It has beenestimated that K88 + ETEC are responsible for more
than half of the piglet mortality which occurs annually
[32].
Oral administration of IgY offers a potential prophy-
lactic and therapeutic approach for controlling E. coli-in-
duced diarrhea in piglets. IgY has been shown to
successfully control intestinal infections of E. coli K88,
K99, 987P, and F18 in young pigs [27, 33, 34]. Yokoyama
et al. [27] showed that orally administered crude IgY
(the water-soluble fraction) generated against E. coli
K88, K99, or 987P fimbriaes was protective against infec-
tion from three homologous strains of E. coli in a dose-
dependent manner in colostrum-deprived piglets. In
vitro, E. coli K88, K99, and 987P strains adhered equally
to porcine epithelial cells from the duodenum and ileum
but failed to so in the presence of homologous anti-
fimbrial IgY [27].
The group of Marquardt [26, 34] from the University
of Manitoba in Canada carried out some excellent stud-
ies on the passive protective effects of IgY against ETEC
K88 fimbriae in neonatal and early-weaned piglets. In an
animal feeding study, 21-day old pigs were orally chal-
lenged with high doses of ETEC K88 at 0 and 5 h of the
experiment. They were then oral administered with
crude IgY (the water-soluble fraction) three times a day
for two consecutive days after the first E. coli challenge.
Control piglets (treated with IgY from non-immunized
hens) had severe diarrhea within 12 h and lost weight
and 30 % of the pigs died within 48 h of infection. In
contrast, the pigs given IgY from immunized hens exhib-
ited no signs of diarrhea 24 and 48 h after treatment,
and had a positive weight gain. Furthermore, this group
performed studies on the practical use of IgY in a field
trial. Their experiment showed suppression of the inci-
dence and severity of diarrhea in 14-18-day-old weaned
Table 1 Effect of IgY against diarrhea caused by bacterial pathogens in piglets
Items Mortality, % Outcome measure
considered-Mortality
(M) or Diarrhea (D)
Intervention Control
Prophylactic effect
Ref. Pathogens Piglet age
Imberechts et al. [33] F18+ ETEC Weaned (21–28 d) 33 66 D
F18+ ETEC Weaned (21–28 d) 25 75 D
F18+ ETEC Weaned (21–28 d) 0 25 M
Marquardt et al. [34] K88+ ETEC Neonatal (3-day-old) 12.5 62.5 M
K88+ ETEC Weaned (21-day-old) 0 30 M
K88+ ETEC Weaning (14-18-days-old) 1.9 3.9 D
Owsu-Asiedu et al. [36] K88+, F18+, F41+ ETEC Early-weaned (10-day-old) 30 73 D
ETEC K88+, F18, F41 Early-weaned (10-day-old) 33 100 D
Owsu-Asiedu et al. [37] K88 + ETEC Early-weaned (10 ± 1 days old) 6.6 40 M
Owsu-Asiedu et al. [38] K88 + ETEC Early-weaned (10-day-old) 0 33 M
Chernysheva et al. [76] K88 + ETEC Newly weaned (about 22-day-old) 66 58.3 D
Chu et al. [86] K88 + ETEC Neonatal (3-day-old) 16.7 66.7 M
Li et al. [83] K88 + ETEC Weaned (40-day-old) 0 75 D
Therapeutic effect
Ref. Pathogens Piglet age
Yokoyama et al. [27] K88 + ETEC Newborn 0 86 M
K99 + ETEC Newborn 0 100 M
987P + ETEC Newborn 0 80 M
Yokoyama et al. [87] F18+ ETEC Weaned (28-day-old) 0 11 D
Yang et al. [88] K88 + ETEC Newborn 0 85.7 M
K99 + ETEC Newborn 0 100 M
987P + ETEC Newborn 0 80 M
Xu et al. [89] K88 + ETEC Newborn 0 33.3 M
K99 + ETEC Newborn 0 66.7 M
987P + ETEC Newborn 0 50 M
Chu et al. [86] K88 + ETEC Weaned (21-day-old) 0 25 M
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than those fed a commercial diet containing an anti-
biotic. The number of pigs in this study was not large
and it would be desirable to repeat this study with a
greater number of animals.
In another study with F18+ E. coli, it was shown that
the F18 antibodies diminished the incidence of diarrhea
and death in weaned piglets infected with F18+ E. coli
[33]. Zuniga et al. [35] also reported that weaned pigs
fed a basal feed plus 5 % (w/w) egg powder with IgY
antibodies against the same fimbrial variant (F18ab or
F18ac) were fully protected when the pigs were chal-
lenged with F18+ E. coli.
In addition to reducing the incidence and severity of
piglet diarrhea, several studies have shown that IgY has
growth promoting effects in early-weaned pigs, similarto spray-dried animal plasma and spray-dried porcine
plasma [36–39]. Table 3 shows the results of an experi-
ment where the performance of pigs fed specific anti-K88
antibodies was compared with that of pigs fed diets sup-
plemented with zinc oxide, fumaric acid or antibiotics
after oral ETEC K88 challenge [37]. All four feed additives
successfully increased pig performance compared with
unsupplemented pigs with significant reductions observed
in scour score and piglet mortality. In this experiment,
IgY was equal to antibiotics in enhancing pig performance.
Table 4 shows the effects of adding egg yolk containing
specific anti-K88 antibodies (EGG), EGG-exchange, or
spray dried porcine plasma to a corn-soybean meal-based
(CON) diet on performance, plasma urea and weight of
pancreas of weaned pigs that were not challenged with
ETEC K88 challenge [39]. The results show that addition
Table 2 Effect of IgY against diarrhea caused by viral pathogens in piglets
Items Mortality, % Outcome measure
considered-Mortality
(M) or Diarrhea (D)
Intervention Control
Prophylactic effect
Ref. Pathogens Piglet age
Kweon et al. [66] PEDV Neonatal (3-day-old) 26 58 M
PEDV Neonatal (3-day-old) 41 71 M
PEDV Neonatal (3-day-old) 50 66 M
Zuo et al. [61] TGEV Newborn 12.5 57 M
Vega et al. [73] Human Rotavirus Neonatal (1-day-old) 0 100 D
Therapeutic effect
Ref. Pathogens Piglet age
Song et al. [67] PEDV Neonatal (1-day-old) 16.7 100 M
Cui et al. [62] TGEV, PEDV Neonatal (1-day-old) 0 100 M
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concentration, and increased feed intake by 23 % and
tended to increase weight gain by 28 % in phase II. This
study indicates that inclusion of EGG in the diets for pigs
immediately after weaning can significantly affect their fu-
ture growth performance. Unfortunately, limited numbers
of pigs were used in this study and a repeat with greater
numbers would certainly be welcomed.
Although adhesin-mediated colonization is a precondi-
tion for ETEC pathogenesis, enterotoxins are thought to
be the central virulence determinants leading to diarrhea
diseases and may also play a role in the colonization
process [30, 40, 41]. Therefore, the ideal protective agent
against ETEC infection should include protection against
both adhesin antigens and enterotoxins [30]. In contrast
with LTB and STa, enterotoxins STa and STb are poorly
immunogenic because of their small size, but they can
attain immunogenicity when coupled chemically or gen-
etically to an appropriate carrier [42, 43]. In order to
make useful toxoids, we constructed polyvalent entero-
toxin STa-LTB-STb DNA and protein vaccines endowing
immunogenicity to both STa and STb [44]. Laying hensTable 3 Effect of IgY, zinc oxide, fumaric acid and antibiotics on the
pigs fed diets based on pea protein concentrate
Items Control IgY Z
Weight gain, g/d 100.9 151.2 1
Feed intake, g/d 141.0 208.1 2
Feed conversion 1.39 1.38 1
Scour score 2.7 1.3 1
Mortality, % 40.0 6.6 1
Villus height, m 355 564 4
Crypt depth, m 204 183 1
Villous height/crypt depth 1.7 3.1 2
Owusu-Asiedu et al. [37]were immunized with DNA vaccines and obtained anti-
toxic antibodies from egg yolks and this was confirmed
by indirect ELISA. The polyvalent DNA vaccine pCI-
STa-LTB-STb expressed the STa-LTB-STb fusion peptide
in vitro in cultured Hela cells. These egg yolk antibodies
were able to neutralize the natural toxicity of STa and
LTb with the highest dilution of 1/2 and 1/32 in a suck-
ling mouse assay [45]. These results indicate that the re-
combinant STa-LTB-STb protein has the potential to
serve as an effective and convenient polyvalent toxoid
which can provide broad protection against ETEC-
induced diarrhea. This study was conducted with mice
and a piglet study should be conducted to confirm these
findings.
Salmonella
Salmonella infection has been recognized as one of the
most common foodborne diseases in humans, causing
1.4 million cases with an estimated economic impact of
$2.4 billion each year in the United States [46, 47]. This
disease can occur via foodborne transmission, animal
contact, or environmental spread [48, 49], and farmperformance and intestinal morphology of 10 to 24 day old
inc oxide Fumaric acid Carbadox SEM
58.9 155.4 152.6 16.6
14.7 211.6 222.4 15.3
.35 1.36 1.45 0.04
.4 1.3 1.1 -
3.3 6.6 13.3 -
88 573 570 20.0
90 207 204 10.1
.6 2.8 2.8 0.11
Table 4 Effect of EGG, EGG-X, or SDPP on performance, plasma
urea and pancreas weight of weaned pigs fed diets based on
corn-soybean meal1
Items Control EGG EGG-X SDPP SEM
Weight gain, g/d
d 0-14 124b 151ab 128b 185a 12.4
d 14-25 332 425 349 398 25.9
Feed intake, g/d
d 0-14 191 219 197 222 12.3
d 14-25 530b 655a 583ab 610ab 37.4
Feed conversion
d 0-14 1.43 1.43 1.47 1.18 0.067
d 14-25 1.54 1.54 1.67 1.54 0.033
Plasma urea N, mmol/L
d 0-14 3.8 3.9 4.3 3.7 0.34
d 14-25 3.4a 3.0b 3.6a 2.6b 0.22
Pancreas, g/kg of body weight 1.07b 1.22ab 1.34a 1.08b 0.071
Heo et al. [39]
1EGG, egg yolk obtained from hens immunized with ETEC K88 antigens;
EGG-X, 650.0 g/kg normal egg and 350.0 g/kg inulin; SDPP, spray dried
porcine plasma
abMeans in a row followed by same or no letter do not differ (P > 0.05)
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losis [50, 51]. Therefore, it is important to control this
disease, not only to reduce productive losses in domestic
livestock, but also to prevent its transmission into the
human food chain. Salmonella species, S. enteritidis and
S. typhimurium, in particular, are thought to be the
major agents of human salmonellosis [46]. They are
non-host serotypes which can cause disease syndromes
like gastroenteritis and systemic infectious in a wide
range of animal species, including humans.
Studies by Yokoyama et al. [52] investigated the effi-
cacy of IgY antibodies specific for outer membrane pro-
tein (OMP), lipopolysaccharide (LPS), or flagella (Fla)
for controlling S. typhimurium or S. enteritidis. They
treated mice orally with an appropriate placebo or puri-
fied IgY following a challenge with S. enteritidis. Anti-
body treatment resulted in survival rates of 80, 47 and
60 % using OMP-, LPS-, and Fla-specific antibodies, in
contrast to survival rates of only 20 % in control mice.
In the S. typhimurium trial, the survival rate was 40, 30
and 20 % using OMP-, LPS-, or Fla-specific antibodies,
in contrast to 0 % in the control mice. These preliminary
results suggest that antibodies against specific Salmon-
ella proteins can control salmonellosis when orally ad-
ministrated to mice.
Studies with pigs have been reported [53, 54]. Unfor-
tunately, reports where similar benefits of IgY to those
found in mice were not obtained with pigs. Mathew
et al. [53] found that feeding egg yolk powder contain-
ing anti-Salmonella IgY antibodies may not beparticularly effective in reducing Salmonella shedding
in pigs. In this experiment, specific egg yolk powder de-
rived from chickens challenged with purified Salmon-
ella typhimurium antigens (fimbrial protein, OMP, and
LPS) was included in swine feed. Treatments were pro-
vided beginning on day 3 of the experiment, and all
pigs were challenged with Salmonella typhimurium on
day 7. Fecal samples were collected on days 0, 7, 8, 12,
14, 21, 58, 88, and 118 to determine shedding of Sal-
monella. The results showed that in-feed IgY antibodies
did not diminish the shedding of Salmonella, and was
inferior to antibiotic treatment. The failure of IgY to
improve performance is suspected to be due to the fact
that the invasive nature of Salmonella allowed the or-
ganism to by-pass the gut and the dietary treatments by
moving through vascular and/or lymphatic routes dir-
ectly into the colon [55–57]. However, available data
are still too limited to allow reliable conclusions regard-
ing the possible efficacy of IgY to control Salmonella
infection in swine.
Antiviral and performance effects
Porcine transmissible gastroenteritis virus
Porcine transmissible gastroenteritis virus (TGEV), a
porcine coronavirus, can cause a highly contagious en-
teric infection in swine of all ages [58]. The infected pig-
lets develop significant clinical signs, including vomiting,
emaciation and severe diarrhea. The disease is especially
severe in the animals less than 2 weeks old with a mor-
tality of nearly 100 % [59, 60]. With the lack of success-
ful vaccines to prevent a TGE outbreak, the disease
occurs frequently in swine farms. It has been shown that
specific IgY has great potential as an alternative prophy-
lactic approach like colostral antibodies against TGEV
[61, 62]. In a prophylactic efficacy experiment, oral ad-
ministration with IgY significantly increased newborn
piglet survival rate (87.5 %) after challenge exposure
compared with the control (43 %), whereas the thera-
peutic effects demonstrate that mortality was dramatic-
ally reduced by orally administered IgY in two farms
that showed TGEV positive results [61]. Unfortunately,
piglet performance was not monitored in this study.
Porcine epidemic diarrhea virus
Porcine epidemic diarrhea virus (PEDV) is another im-
portant enteric viral pathogen that is responsible for
neonatal piglet diarrhea [63, 64]. Although the clinical
symptoms of PEDV infection are similar to TGEV in-
fection, PEDV is antigenically different from TGEV.
Epidemiological observations have indicated that the
spread of disease seems to be slower, but rather persist-
ent compared with a TGEV outbreak [65]. It has been
shown that IgY can be an alternative method for confer-
ring protection in piglets against PEDV [62, 66, 67]. IgY
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exposures. The field application of IgY from three farms
also revealed the survival rate was increased signifi-
cantly in pigs treated with IgY (49.24 %) compared with
a control group (33.71 %).
Rotavirus
Rotavirus is a major pathogen of infectious gastroenteritis,
not only in children and infants, but also in domestic
animals. In humans alone, it has been estimated that
rotavirus infections result in several million deaths each
year [68]. Animals are also seriously affected by this virus.
Rotavirus from calves, pigs, mice, foals, infant humans,
lambs, chickens, and turkey are antigenically related [69].
Therefore, the appropriate anti-rotavirus antibodies will
react with the virus present in any of these species.
IgY has been shown to successfully control intestinal
infection of rotavirus in newborn calves and mice [70–73].
Studies with pigs have been reported and similar positive
results were obtained [74]. A passive treatment based on
human rotavirus specific IgY antibodies not only pre-
vented gnotobiotic piglets from developing diarrhea
caused by the prevalent strain of Wa G1P [8] HRV, but
also significantly reduced the amount of infectious virus
shed compared with a negative control group.
Current challenges
There are many obstacles that can limit the use of
IgY for the control of diarrhea diseases in swine. The
most important issues which need to be addressed
are as follows.
The stability of IgY in the gastrointestinal tract when they
are fed to swine
Although the beneficial effects of pathogen-specific IgY
in animals have been known for about 20 years, results
on the experimental application of these antibodies in
swine have not always been consistent. There are severalTable 5 Effect of encapsulated IgY on performance and the inciden
Items No. of
pigs
Percentage of pigs with diarrhea
9 h 24 h
Negative control, unchallenged 4 0 % (0.5) 0 % (0)
Positive control 4 75 % (2.5) 75 % (2.5)
Non-encapsulated IgY 4 100 % (2.0) 75 % (1.3)
Microencapsulated IgY 4 75 % (2.0) 0 % (0)
Aureomycin 4 100 % (2.0) 50 % (2.0)
Li et al. [83]
1All pigs except negative control were orally challenged with 5 mL of viable E. coli K
untreated (positive control) or treated three times (−1, 4 and 9 h after bacterial cha
with 0.4 g non-encapsulated IgY, 2 g of microencapsulated IgY (equivalent to 0.4 g
3 days after challenge
2FC score is the mean fecal consistency score: 0, normal; 1, soft feces; 2, mild diarrh
have diarrhea
3Means in a column followed by same or no letter do not differ (P > 0.05)reports where IgY failed to improve pig performance
[75, 76]. The most likely explanation for the failure of
the treatment is that the antibody failed to survive pas-
sage through the gastrointestinal tract as a result of its
susceptibility to proteolysis [77]. IgY, being a glycopro-
tein, is sensitive to the same denaturing conditions as
most proteins. It has been reported that IgY is fairly re-
sistant to digestion by intestinal proteases, but the activ-
ity of IgY was decreased at pH 3.5 or lower and almost
completely lost with irreversible change at pH 3 [78]. In
addition, the inactivation at low pH is further enhanced
by the presence of pepsin. In contrast to very young
pigs, the stomach of older pigs has a low pH and pepsin,
and therefore IgY may not be effective in controlling
post-weaning E. coli diarrhea in older animals.
Yokoyama et al. [79], in an excellent study, detected
the rate of IgY passage through the gastrointestinal tract
of pigs and its ability to retain its activity in the different
sections of the tract. Their results demonstrated that IgY
is readily absorbed within 24 h by the newly born pig.
IgY has a serum half-life of 1.85 days in newborn pigs,
which is shorter than the reported serum half-life of 12
to 14 days for homologous IgG (colostral antibodies).
The amount of IgY absorbed into the circulation when
administered in pigs decreased with increasing age of
pigs.
Since the primary target site of IgY is the small intes-
tine, in order for it to function, it must be able to survive
passage through the harsh environmental conditions
found in the stomach. Microencapsulation techniques
have been developed to protect IgY from gastric inacti-
vation [77, 80–83]. Table 5 shows the results of an ex-
periment where chitosan-alginate microcapsules were
used for oral delivery of egg yolk immunoglobulin in
weaned pigs challenged with enterotoxigenic E. coli
K88 [83]. The percentage of pigs with diarrhea 24 h
after treatment and the diarrhea score were improved
in pigs receiving encapsulated IgY compared with non-ce of diarrhea in pigs challenged with K88+ ETEC1
after specific times (Fecal score in brackets2) Weight gain,
g3
Recovery
rate, (%)48 h 72 h
0 % (0.4) 0 % (0) +1400 ± 129a ——
75 % (2.0) 75 % (2.0) −162.5 ± 25d 0 %
25 % (1.0) 0 % (0) +937.5 ± 111b 100 %
0 % (0) 0 % (0) +1325 ± 119a 100 %
75 % (1.5) 50 % (1.5) +650 ± 71c 50 %
88 organisms (1011 cfu/mL per pig) at time 0 h. Challenged pigs were left
llenge) on the first day and twice a day for two consecutive days each time
of IgY) or 0.25 g of aureomycin. Diarrhea and weight gain were assessed for
ea; 3, severe diarrhea. Pigs with a fecal score of < 1 were considered not to
Li et al. Journal of Animal Science and Biotechnology  (2015) 6:40 Page 8 of 10encapsulated IgY. In addition, weight gain over the
three day period was significantly higher in pigs receiv-
ing encapsulated IgY compared with non-encapsulated
IgY. Both encapsulated and non-encapsulated IgY treat-
ments were numerically superior to an aureomycin
treated group. However, this process will undoubtedly
add additional costs. Additional study will be needed
before microencapsulation can be applied under com-
mercial conditions.
The stability of IgY when subjected to feed processing
Egg-yolk antibodies can be administrated to young pigs
either as a preventive or prophylactic treatment or as a
therapeutic treatment after infection occurs. It appears
that adding antibodies to swine feeds in the form of
whole egg powder or whole yolk powder may be the
most practical method of inclusion of IgY for preventive
or prophylactic treatment. It is not known if IgY anti-
bodies can tolerate heat-based feed processing tech-
niques such as pelleting. Presumably the stability of IgY
antibodies would be similar to that for enzymes and that
stability would be greatly influenced by temperature,
duration of heat treatment and cooling period as well as
the moisture content of the diet. It is well known that a
change in moisture content from 95 to 90 or 85 % dry
matter can dramatically decrease the stability of proteins
when heated to high temperatures. Preliminary studies
by Marquardt et al. [84] have demonstrated that low
temperature steam pelleting (70 °C) did not reduce
antibody titer. Further studies need to be carried out on
this problem
Specificity of IgY
IgY is an attractive and effective alternative approach to
antibiotics due to its high specificity. It should be noted
that swine are exposed to many infectious agents in
commercial operations and therefore the swine industry
will benefit more from IgY antibodies if they are pro-
duced against a mixture of common disease causing
organisms rather than one specific disease. If this ap-
proach works well, it may help to justify, to some extent,
commercial application of these antibodies.
Amount of product added to the diet or administrated by
gavage
The efficacy of IgY in the gastrointestinal tract is related
to two factors namely the dose of antibodies and the
concentration of pathogen. The results of Yokoyama
et al. [79] demonstrated that antibodies pass through the
digestive system within a relatively short period of time
(slightly more than 24 h). In addition, they can reach all
sections of the gastrointestinal tract in less than 10 h.
The supply of antibodies in the intestine must be suffi-
ciently high to prevent binding of pathogen to theintestinal receptors. The antibody must also be continu-
ously or nearly continuously available in the intestine.
Studies by Marquardt et al. [34] showed that 1.5 g per
day per piglet was sufficient to prevent diarrhea induced
by infection with 1010 ETEC and the addition of 0.2 % of
egg-yolk antibody in the diet was preventive against diar-
rhea in commercial farms. However, a considerable
amount of additional research must be carried out to
identify the best antigens to use and the appropriate pre-
vention or treatment protocols for control of intestinal
pathogens such as different strains of E. coli.The production cost of high quality IgY antibodies
At present, the production cost of high quality IgY anti-
bodies is higher than the cost of routine antibiotic inclu-
sion [84]. Therefore, the development of methods for
large-scale production of IgY which produce a high re-
covery and purity of IgY are needed. The method should
be simple, economical and require few chemicals. In
addition, there is no consensus on the most suitable IgY
extraction method for commercial application [20] and
this requires further study.Conclusions
Oral administration of specific IgY appears to have con-
siderable potential as a means of controlling diarrhea
diseases and exerting growth-promoting activity in
swine. IgY technology will probably provide the best al-
ternative to antibiotics. Some advantages of IgY in the
control of swine diseases are:
1) They are highly effective.
2) They are highly cost-effective with only a small
amount of antibody required per pig.
3) Collection of eggs is non-invasive.
4) The treatment is safe and live organisms are not
used.
5) The procedure is environmentally friendly.
6) No toxic residues are produced and there is no
development of resistance.
7) The treatment can be used to control many different
types of pathogens.
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